Natural Management of H. pylori Infection
Evidence-based natural approaches — broccoli sprouts, cranberry, Lactobacillus reuteri, mastic gum, and lactoferrin — that suppress H. pylori and improve eradication outcomes
Helicobacter pylori is a spiral-shaped bacterium that lives in the stomach lining of roughly half the world's population. Most people carry it without symptoms for decades, but it is the leading cause of stomach ulcers and the single most important environmental risk factor for gastric cancer. While antibiotic triple therapy remains the standard treatment, rising resistance rates are making eradication harder — and several natural compounds have demonstrated real ability to suppress H. pylori or meaningfully improve antibiotic success rates in controlled human trials. Broccoli sprouts, cranberry juice, the probiotic strain Lactobacillus reuteri, mastic gum, and lactoferrin all have peer-reviewed evidence behind them [1][2][3][4][5].
What Is H. pylori and Why Does It Matter?
Helicobacter pylori is uniquely adapted to survive in the highly acidic stomach environment. It secretes urease, an enzyme that converts urea into ammonia, which neutralizes stomach acid in its immediate vicinity and allows it to burrow into the mucous lining. Once established, it triggers chronic low-grade inflammation (gastritis) that persists indefinitely without treatment.
For most people, this smoldering inflammation never causes noticeable symptoms. But over years or decades, it can erode the protective mucus layer and lead to peptic ulcers — and in a subset of patients, the chronic inflammation progresses toward intestinal metaplasia and, eventually, gastric cancer. H. pylori is classified by the World Health Organization as a Group 1 carcinogen (definite cause of cancer in humans).
You might suspect H. pylori if you experience: recurrent bloating or burping, a burning sensation in the upper abdomen that improves with eating then worsens 2–3 hours later, frequent nausea, or a history of stomach ulcers. Diagnosis is confirmed by a urea breath test, stool antigen test, or endoscopic biopsy — not by symptoms alone.
The Problem With Antibiotics Alone
Standard treatment is 14 days of "triple therapy": a proton pump inhibitor (omeprazole or similar) combined with two antibiotics, typically clarithromycin and amoxicillin. Eradication rates with this protocol have dropped from over 90% in the 1990s to 70–80% in many regions, driven by rising clarithromycin resistance. Failed eradication leads to repeat courses with stronger antibiotic combinations, greater gut microbiome disruption, and increasing frustration.
This is where natural adjuncts become genuinely useful — not as replacements for antibiotics in most cases, but as evidence-based additions that improve eradication rates and reduce side effects.
Broccoli Sprouts: Sulforaphane Against H. pylori
Sulforaphane, a compound released when cruciferous vegetables are chewed or chopped, is one of the most potent natural antibacterial agents studied against H. pylori. Unlike antibiotics, it can penetrate the mucous layer where H. pylori hides and appears to work through multiple mechanisms simultaneously, making resistance development harder.
A 2009 randomized controlled trial enrolled 48 H. pylori-infected volunteers who consumed either 70 grams of broccoli sprouts (providing approximately 420 μmol of the sulforaphane precursor glucoraphanin) or alfalfa sprouts as placebo for eight weeks [2]. The broccoli sprout group showed significant reductions in urea breath test values and stool antigen levels — both direct markers of H. pylori activity — as well as lower serum pepsinogen I/II ratios, indicating reduced gastric inflammation. Effects were meaningful but not curative; H. pylori was suppressed, not eradicated.
Practical guidance: Fresh broccoli sprouts (70 g/day) are more potent than mature broccoli. Chewing thoroughly activates the myrosinase enzyme needed to convert glucoraphanin to active sulforaphane. Cooking significantly reduces potency. Broccoli sprout supplements vary widely in quality; look for products standardized to sulforaphane yield. See our Sulforaphane page for more on this compound.
Cranberry: Blocking Bacterial Attachment
Cranberry proanthocyanidins (PACs) are best known for preventing urinary tract infections by stopping bacteria from adhering to bladder walls. The same mechanism applies in the stomach: H. pylori relies on adhesins to anchor to gastric epithelium, and cranberry PACs physically block this attachment, making the bacteria easier to clear.
A 2005 double-blind RCT of 189 adults found that 90 days of cranberry juice consumption produced a 14.4% negative conversion rate (H. pylori cleared) versus 5.4% in the placebo group [6]. A larger 2021 RCT with 522 H. pylori-positive adults confirmed the finding: high-dose proanthocyanidin-standardized cranberry juice (44 mg PAC per 240 mL serving, twice daily for 8 weeks) reduced infection rates by approximately 20% compared to placebo [4]. Importantly, encapsulated cranberry powder was ineffective in this trial, suggesting the juice matrix or liquid delivery matters.
Practical guidance: Use proanthocyanidin-standardized cranberry juice, not the sweetened cocktail commonly sold in stores. Aim for 240–480 mL of high-PAC juice daily. This approach is best as a suppressive or adjunctive strategy, not standalone therapy for active infection.
Lactobacillus reuteri: A Probiotic That Improves Eradication
Not all probiotics are created equal for H. pylori. The strain Lactobacillus reuteri DSM 17648 has been specifically studied for its ability to co-aggregate with H. pylori cells — physically clustering around the bacteria and facilitating their removal during normal gastric emptying — while also competing for adhesion sites.
A 2023 randomized double-blind placebo-controlled trial enrolled 90 patients who all received standard triple therapy, with half receiving the L. reuteri supplement and half receiving placebo [3]. The eradication rate in the probiotic group was 91.1% compared to 68.9% in the control group — a 22.2 percentage point improvement. Beyond eradication rates, the probiotic group reported fewer antibiotic side effects including less nausea, abdominal pain, and headache. This trial represents some of the strongest evidence for a probiotic specifically enhancing H. pylori eradication outcomes.
Practical guidance: Look for products containing L. reuteri DSM 17648 specifically — this strain designation matters, as other L. reuteri strains may not have the same co-aggregation mechanism. Take during and after antibiotic courses. General probiotic support during and after H. pylori treatment is also useful for protecting the gut microbiome from antibiotic disruption. See our Probiotics page for broader guidance.
Mastic Gum: An Ancient Resin With Modern Evidence
Mastic gum is a resin produced by the mastic tree (Pistacia lentiscus), native to the Greek island of Chios and widely used in traditional Mediterranean medicine for stomach complaints. In 1998, a letter in the New England Journal of Medicine reported that just 1 mg of mastic gum daily killed H. pylori in vitro — reducing viable bacteria by a factor of 1,000 (99.9%) — enough to generate significant research interest [1].
While subsequent human trials have shown more modest results than that dramatic in vitro finding, mastic gum has demonstrated genuine antibacterial and anti-ulcer activity in several controlled studies. It appears to work through a combination of mechanisms: direct bactericidal activity, inhibition of H. pylori urease, and anti-inflammatory effects on the gastric mucosa.
Practical guidance: Standard dosing in human studies has been 350–1,000 mg/day of pure mastic gum resin. Quality varies considerably between brands; look for products standardized from authentic Chios mastic. This is best used as a supportive or maintenance approach rather than as primary treatment.
Lactoferrin: Improving Antibiotic Outcomes
Lactoferrin is an iron-binding protein found in colostrum, breast milk, saliva, and tears — part of the innate immune system's frontline defense against pathogens. It binds iron that bacteria need for growth, disrupts bacterial cell membranes, and has direct antimicrobial activity against H. pylori. As an adjunct to antibiotic therapy, it appears to work synergistically.
A 2009 meta-analysis pooled nine randomized controlled trials involving 1,343 participants comparing lactoferrin-supplemented H. pylori eradication regimens to standard therapy alone [5]. Lactoferrin supplementation raised eradication rates from 74.4% to 86.6% and simultaneously reduced the rate of adverse effects from 16.3% to 9.1% — fewer treatment side effects alongside better outcomes. This combination of improved efficacy and reduced adverse effects makes lactoferrin a particularly attractive adjunct.
Practical guidance: Bovine lactoferrin (bLF) at 200–300 mg/day is the form used in most research. It can be taken throughout an antibiotic course without interfering with antibiotic absorption. See our Bovine Colostrum page for related information on colostrum-derived immune proteins.
Should You Treat H. pylori Without Antibiotics?
For mild, incidental H. pylori carriage with no ulcers, no symptoms, and no family history of gastric cancer, some people reasonably opt to monitor and use natural suppression strategies. However, the current medical consensus is that confirmed H. pylori infection warrants eradication — the long-term cancer risk reduction from successful treatment is substantial and well-established. Natural approaches work best as complementary strategies that improve the odds of successful eradication when combined with standard therapy, not as replacements for it.
If antibiotic courses have failed, or if you prefer to exhaust supportive options first in a low-risk scenario, the combination of broccoli sprouts, proanthocyanidin-rich cranberry, L. reuteri DSM 17648, and mastic gum represents a reasonable evidence-based natural protocol.
Evidence Review
Mastic Gum (Huwez et al., 1998)
The foundational study for mastic gum's reputation against H. pylori is a 1998 letter in the New England Journal of Medicine [1]. Huwez and colleagues reported that 1 mg of purified mastic gum killed H. pylori in vitro, reducing viable cell counts by a factor of 1,000. While this was not a clinical trial in humans, the publication in a top-tier journal and the magnitude of the in vitro effect generated sustained research interest. Subsequent clinical studies have generally shown more modest eradication effects as monotherapy, consistent with the gap between in vitro potency and in vivo clinical outcomes that is common in natural product research. The evidence base for mastic gum as a human treatment remains suggestive rather than definitive, but it is more substantial than for most herbal stomach remedies.
Broccoli Sprouts (Yanaka et al., 2009)
This randomized controlled trial is the strongest human evidence for sulforaphane against H. pylori [2]. Forty-eight H. pylori-infected volunteers were randomized to 70 g/day of broccoli sprouts or alfalfa sprouts (placebo) for eight weeks. Outcome measures included the urea breath test (UBT, measuring active urease activity as a proxy for bacterial load), stool H. pylori antigen, and serum pepsinogen I/II ratio (a marker of gastric mucosal health).
Results: UBT values and stool antigen concentrations decreased significantly in the broccoli sprout group compared to placebo (p < 0.001). Serum pepsinogen I/II ratios normalized more frequently in the treatment group, suggesting reduced mucosal atrophy. Eight weeks post-intervention, UBT and antigen values returned toward baseline, indicating the effect was suppressive rather than eradicative — H. pylori was still present but at reduced levels with reduced inflammatory consequences. Study limitations include small sample size (n=48), short intervention duration, and no follow-up beyond 8 weeks post-treatment. The primary value of this study is establishing proof of concept for the clinical suppressive activity of sulforaphane.
Lactobacillus reuteri DSM 17648 (Ismail et al., 2023)
This 2023 RCT is methodologically strong: double-blind, placebo-controlled, with 90 patients (45 per group) all receiving standard 14-day triple therapy (proton pump inhibitor + clarithromycin + amoxicillin), with randomization to L. reuteri DSM 17648 or placebo [3]. Eradication was confirmed by urea breath test 4 weeks after completing antibiotics.
Intention-to-treat eradication rate: 91.1% (probiotic) vs. 68.9% (placebo), p = 0.007. Per-protocol rate: 93.0% vs. 72.1%. The absolute difference of 22.2 percentage points is clinically meaningful given that rates below 80% are considered treatment failure requiring escalation. Secondary outcomes showed significantly greater reductions in gastrointestinal symptom scores (indigestion, abdominal pain, constipation) and fewer antibiotic-related adverse effects in the probiotic group. Limitations: single-center design, relatively small sample, conducted in Malaysia where clarithromycin resistance patterns may differ from other regions. Nevertheless, this represents the most rigorous recent evidence for a specific probiotic strain improving H. pylori outcomes.
Cranberry (Zhang et al., 2005; Li et al., 2021)
Two double-blind placebo-controlled RCTs establish a consistent effect of proanthocyanidin-rich cranberry on H. pylori.
Zhang et al. 2005 (n=189, 90-day intervention) found that 14.4% of cranberry juice drinkers converted from H. pylori-positive to negative at day 35 vs. 5.4% of placebo controls [6]. By day 90, the absolute difference had narrowed as some placebo spontaneous clearance occurred, but remained nominally significant. The study used 250 mL of commercially available cranberry juice twice daily.
Li et al. 2021 (n=522, 8-week intervention) used a more rigorous design with proanthocyanidin-standardized juice (44 mg PAC/serving, twice daily = 88 mg PAC/day) and tested multiple doses against placebo [4]. Compliance was 94.25%. The high-dose cranberry juice reduced H. pylori prevalence by approximately 20% relative to placebo. Notably, encapsulated cranberry powder — identical active compounds but different delivery form — showed no significant effect, raising important questions about bioavailability and the role of the juice matrix. The mechanism (anti-adhesion via proanthocyanidins blocking BabA and SabA adhesins on H. pylori) is well-characterized in vitro. Limitations: cranberry does not appear capable of eradicating established infection in the short term; suppressive effects may require long-term consistent use, and the optimal dose and form remain incompletely defined.
Lactoferrin (Zou et al., 2009)
This meta-analysis searched multiple databases and identified nine eligible RCTs involving 1,343 participants who received lactoferrin-supplemented H. pylori eradication regimens versus standard regimens alone [5]. Lactoferrin dosages in included trials were typically 200–300 mg/day of bovine lactoferrin, administered during the antibiotic course.
Pooled eradication rates: 86.6% (lactoferrin) vs. 74.4% (standard therapy alone), a 12.2 percentage point improvement. The lactoferrin effect was consistent across triple therapy and sequential therapy subgroups. Adverse event rate: 9.1% (lactoferrin) vs. 16.3% (standard), particularly driven by reduced nausea. This dual benefit — higher efficacy and fewer side effects — from a generally well-tolerated food protein (lactoferrin is abundant in human and bovine milk) is clinically notable. Limitations: heterogeneity across included trials in antibiotic protocols, lactoferrin formulations, and geographic H. pylori resistance patterns. The meta-analysis is now 15 years old and antibiotic resistance patterns have evolved, though the lactoferrin mechanism (iron sequestration, membrane disruption) is not affected by antibiotic resistance.
Overall Evidence Assessment
The evidence supports a graduated view of these natural approaches:
- Strongest evidence for clinical benefit: L. reuteri DSM 17648 as adjunct to antibiotic therapy (single RCT, strong effect, recent); lactoferrin as adjunct (meta-analysis of 9 RCTs).
- Good evidence for suppression/adjunct use: Broccoli sprouts/sulforaphane (RCT confirming bacteriostatic effect); cranberry proanthocyanidins (two RCTs, consistent suppressive effect).
- Early-stage or primarily in vitro evidence: Mastic gum (strong in vitro, inconsistent human data).
No natural approach has been shown to reliably eradicate H. pylori as monotherapy in controlled human trials. The practical clinical utility is as adjuncts to standard antibiotic therapy (improving eradication rates) or as suppressive maintenance strategies in people who decline or are not candidates for antibiotic treatment.
References
- Mastic gum kills Helicobacter pyloriHuwez FU, Thirlwell D, Cockayne A, Ala'Aldeen DA. New England Journal of Medicine, 1998. PubMed 9874617 →
- Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humansYanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang S, Tauchi M, Suzuki H, Hyodo I, Yamamoto M. Cancer Prevention Research, 2009. PubMed 19349290 →
- Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trialIsmail NI, Muhammad Nawawi KN, Chew Chia Hsin D, et al.. Helicobacter, 2023. PubMed 37614081 →
- Suppression of Helicobacter pylori infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trialLi ZX, Ma JL, Guo Y, Liu WD, Li M, Zhang LF, et al.. Journal of Gastroenterology and Hepatology, 2021. PubMed 32783238 →
- Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapyZou J, Dong J, Yu XF. Helicobacter, 2009. PubMed 19298339 →
- Efficacy of cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trialZhang L, Ma J, Pan K, Go VL, Chen J, You WC. Helicobacter, 2005. PubMed 15810945 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.